Selected article for: "extensive lung damage and lung damage"
Author: Giuseppe Gritti; Federico Raimondi; Diego Ripamonti; Ivano Riva; Francesco Landi; Leonardo Alborghetti; Marco Frigeni; Marianna Damiani; Caterina Micò; Stefano Fagiuoli; Roberto Cosentini; Ferdinando Luca Lorini; Fabrizio Fabretti; Jonathan Morgan; Benjamin M.J. Owens; Karan Kanhai; Jim Cowburn; Marco Rizzi; Fabiano Di Marco; Alessandro Rambaldi
Title: Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
  • Document date: 2020_4_3
    • ID: ajurlkwr_5
    Snippet: Tocilizumab, an IL-6R targeted monoclonal antibody (mAb), received rapid approval in China for treatment of patients with severe COVID-19 and extensive lung damage (National Health Commission of China, 2020; Xu X et al. 2020) . We report preliminary data from 21 patients with COVID-19 who developed serious respiratory complications and were treated with siltuximab, a chimeric mAb that binds to and blocks the effect of IL-6 (NCT04322188). Siltuxim.....
    Document: Tocilizumab, an IL-6R targeted monoclonal antibody (mAb), received rapid approval in China for treatment of patients with severe COVID-19 and extensive lung damage (National Health Commission of China, 2020; Xu X et al. 2020) . We report preliminary data from 21 patients with COVID-19 who developed serious respiratory complications and were treated with siltuximab, a chimeric mAb that binds to and blocks the effect of IL-6 (NCT04322188). Siltuximab is approved by the European Medicines Agency and the Food and Drug Administration of the USA for treatment of adults with multicentric Castleman's disease who are human immunodeficiency virus and human herpes virus-8 negative (EUSA 2019).

    Search related documents:
    Co phrase search for related documents
    • extensive lung damage and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • human immunodeficiency and lung damage: 1
    • human immunodeficiency and monoclonal antibody: 1, 2, 3, 4, 5, 6
    • human immunodeficiency virus and lung damage: 1
    • human immunodeficiency virus and monoclonal antibody: 1, 2, 3, 4, 5, 6
    • lung damage and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • lung damage and respiratory complication: 1, 2
    • mAb target monoclonal antibody and monoclonal antibody: 1, 2, 3, 4, 5, 6
    • mAb target monoclonal antibody and target monoclonal antibody: 1, 2, 3, 4, 5
    • monoclonal antibody and respiratory complication: 1, 2, 3, 4
    • monoclonal antibody and target monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21